Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Clin Lung Cancer. 2013 Jul 1;14(5):581–591. doi: 10.1016/j.cllc.2013.05.002

Table 2.

Associations between Patient Characteristics and EGFR and KRAS Mutation Status

EGFR Mutation Status KRAS Mutation Status
Variable # positive/# tested % Fisher’s exact P value # positive/# tested % Fisher’s exact P value
Gender 0.002 0.03
 Female 47/220 21.4 58/173 33.5
 Male 13/143 9.1 25/117 21.4
Race <0.001 0.05
 Caucasian 47/287 16.4 72/224 32.1
 African American 3/47 6.4 8/40 20.0
 Asian American 9/12 75.0 0/11 0.0
 Other 0/12 0.0 2/10 20.0
Smoking status <0.001 <0.001
 Never smoker 36/75 48.0 4/56 7.1
 Ever smoker 24/286 8.4 78/232 33.6
ECOG PS 0.54+ 0.52+
 0 20/121 16.5 25/99 25.3
 1 24/143 16.8 36/125 28.8
 2+ 3/32 9.4 8/26 30.8
Histology 0.15 0.42
 AdenoCA ±BAC 53/287 18.5 70/228 30.7
 Squamous 6/28 21.4 3/22 13.6
 Adenosquamous 0/14 0.0 4/11 36.4
 NOS* 1/20 5.0 3/17 17.6
 Large Cell 0/8 0.0 2/7 28.6
 Other$ 0/3 0.0 0/2 0.0
Stage 0.73+ 0.23+
 I 9/43 20.9 11/29 37.9
 II 5/33 15.2 9/27 33.3
 III 17/115 14.8 25/93 26.9
 IV 29/172 16.9 38/141 27.0
Brain Metastases 0.50 0.37
 No 49/281 17.4 66/219 30.1
 Yes 11/81 13.6 17/70 24.3
Liver Metastases 0.04 0.18
 No 58/323 18.0 76/252 30.2
 Yes 2/39 5.1 7/37 18.9
Subcutaneous Metastases 0.60 0.07
 No 60/357 16.8 80/285 28.1
 Yes 0/5 0.0 3/4 75.0
Bone Metastases 0.28 0.15
 No 39/257 15.2 65/208 31.2
 Yes 21/105 20.0 18/81 22.2
+

Exact trend test P value

*

Not Otherwise Specified (Poorly Differentiated)

$

Other Histology includes Sarcomatoid (1), Pleotropic (1), NOS (1)